Benoît Rive

1.3k total citations · 1 hit paper
29 papers, 877 citations indexed

About

Benoît Rive is a scholar working on Pharmacology, Psychiatry and Mental health and Biological Psychiatry. According to data from OpenAlex, Benoît Rive has authored 29 papers receiving a total of 877 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 9 papers in Psychiatry and Mental health and 6 papers in Biological Psychiatry. Recurrent topics in Benoît Rive's work include Treatment of Major Depression (19 papers), Tryptophan and brain disorders (6 papers) and Mental Health Treatment and Access (5 papers). Benoît Rive is often cited by papers focused on Treatment of Major Depression (19 papers), Tryptophan and brain disorders (6 papers) and Mental Health Treatment and Access (5 papers). Benoît Rive collaborates with scholars based in France, Denmark and United States. Benoît Rive's co-authors include Dena H. Jaffe, Tom Denee, Delphine Saragoussi, Josep María Haro, Pierre‐Michel Llorca, Lene Hammer-Helmich, Natalya Danchenko, Maëlys Touya, Bengt Jönsson and C. François and has published in prestigious journals such as New England Journal of Medicine, Neurology and The British Journal of Psychiatry.

In The Last Decade

Benoît Rive

27 papers receiving 850 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

2023 110 citations Andreas Reif, István Bitter et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benoît Rive France	17	491	249	243	178	105	29	877
Nadia Iovieno United States	17	413 0.8×	207 0.8×	320 1.3×	187 1.1×	111 1.1×	28	956
Laura Thomas United Kingdom	15	355 0.7×	298 1.2×	278 1.1×	100 0.6×	227 2.2×	24	1.0k
Smadar Valérie Tourjman Canada	4	501 1.0×	238 1.0×	354 1.5×	179 1.0×	132 1.3×	6	879
Alessandra Signoretti Italy	7	319 0.6×	155 0.6×	306 1.3×	91 0.5×	100 1.0×	9	730
Paul‐Egbert Reimitz Germany	15	310 0.6×	205 0.8×	206 0.8×	58 0.3×	95 0.9×	44	1.3k
Maurizio Fava United States	13	536 1.1×	414 1.7×	461 1.9×	135 0.8×	165 1.6×	17	1.2k
Stuart Carney United Kingdom	7	416 0.8×	210 0.8×	347 1.4×	101 0.6×	159 1.5×	10	905
C.M.E. Kremer United States	13	651 1.3×	179 0.7×	569 2.3×	158 0.9×	112 1.1×	34	1.2k
Shane McInerney Canada	15	537 1.1×	291 1.2×	542 2.2×	212 1.2×	296 2.8×	35	1.3k
Robert E. McCue United States	17	475 1.0×	154 0.6×	449 1.8×	127 0.7×	101 1.0×	32	840

Countries citing papers authored by Benoît Rive

Since Specialization

Citations

This map shows the geographic impact of Benoît Rive's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benoît Rive with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benoît Rive more than expected).

Fields of papers citing papers by Benoît Rive

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benoît Rive. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benoît Rive. The network helps show where Benoît Rive may publish in the future.

Co-authorship network of co-authors of Benoît Rive

This figure shows the co-authorship network connecting the top 25 collaborators of Benoît Rive. A scholar is included among the top collaborators of Benoît Rive based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benoît Rive. Benoît Rive is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vieta, Eduard, Celso Arango, Anthony J. Cleare, et al.. (2025). Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. European Neuropsychopharmacology. 93. 29–39. 2 indexed citations

Clemens, Kristin K., Amanda Teeple, Benoît Rive, et al.. (2024). Cost Efficiency of Esketamine Nasal Spray Versus Quetiapine for Treatment Resistant Depression. CNS Spectrums. 29(5). 526–527. 1 indexed citations

Young, Allan H., Pierre‐Michel Llorca, Peter Falkai, et al.. (2024). Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. The British Journal of Psychiatry. 226(2). 72–78.

Oliveira‐Maia, Albino J., et al.. (2024). Estimating the benefit of esketamine nasal spray versus real-world treatment on patient-reported functional remission: results from the ICEBERG study. Frontiers in Psychiatry. 15. 1459633–1459633. 2 indexed citations

Reif, Andreas, István Bitter, Jozefien Buyze, et al.. (2023). Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. New England Journal of Medicine. 389(14). 1298–1309. 110 indexed citations breakdown →

Oliveira‐Maia, Albino J., et al.. (2023). Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study. Frontiers in Psychiatry. 14. 1250987–1250987. 5 indexed citations

Morrens, Joachim, Maju Mathews, Vanina Popova, et al.. (2022). Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression. Neuropsychiatric Disease and Treatment. Volume 18. 1127–1132. 12 indexed citations

Jaffe, Dena H., Benoît Rive, & Tom Denee. (2019). The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 19(1). 247–247. 153 indexed citations

Jaffe, Dena H., Benoît Rive, & Tom Denee. (2019). <p>The burden of suicidal ideation across Europe: a cross-sectional survey in five countries</p>. Neuropsychiatric Disease and Treatment. Volume 15. 2257–2271. 16 indexed citations

10.

Haro, Josep María, François-Xavier Lamy, Bengt Jönsson, et al.. (2018). Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study. BMC Psychiatry. 18(1). 80–80. 6 indexed citations

11.

Hammer-Helmich, Lene, Josep María Haro, Bengt Jönsson, et al.. (2018). Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatric Disease and Treatment. Volume 14. 239–249. 87 indexed citations

12.

Saragoussi, Delphine, Michael Cronquist Christensen, Lene Hammer-Helmich, et al.. (2018). Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study. Neuropsychiatric Disease and Treatment. Volume 14. 1339–1350. 66 indexed citations

13.

Lam, Raymond W., François-Xavier Lamy, Natalya Danchenko, et al.. (2018). Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. Neuropsychiatric Disease and Treatment. Volume 14. 2861–2877. 62 indexed citations

14.

Saragoussi, Delphine, Maëlys Touya, Josep María Haro, et al.. (2017). Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatric Disease and Treatment. Volume 13. 2151–2165. 46 indexed citations

15.

Owen, Randall, C. François, Robert A. Hauser, et al.. (2016). Impact of Reduction in Falls for Patients with PD and nOH: Post Hoc Economic Analyses of Phase 3 Clinical Trial Data on Droxidopa (P1.020). Neurology. 86(16_supplement).

16.

Florea, Ioana, Natalya Danchenko, Mélanie Brignone, et al.. (2015). The Effect of Vortioxetine on Health-related Quality of Life in Patients With Major Depressive Disorder. Clinical Therapeutics. 37(10). 2309–2323.e6. 24 indexed citations

17.

Rive, Benoît, et al.. (2013). Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease. CNS Drugs. 27(7). 573–582. 16 indexed citations

18.

Andrieu, Sandrine, Benoît Rive, Xavier Kurz, et al.. (2007). New assessment of dependency in demented patients: Impact on the quality of life in informal caregivers. Psychiatry and Clinical Neurosciences. 61(3). 234–242. 27 indexed citations

19.

Rive, Benoît, et al.. (2004). Memantine enhances autonomy in moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry. 19(5). 458–464. 31 indexed citations

20.

Auquier, Pascal, S. Robitail, Pierre‐Michel Llorca, & Benoît Rive. (2003). Comparison of escitalopram and citalopram efficacy: A meta-analysis. International Journal of Psychiatry in Clinical Practice. 7(4). 259–268. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact